(ZEAL) Zealand Pharma - CO
Sector: Healthcare | Industry: Biotechnology | Exchange: CO (Denmark) | Market Cap: 19.864m DKK | Total Return: -25.5% in 12m
Avg Turnover: 154M
Qual. Beats: 3
Rev. Trend: 67.7%
Qual. Beats: 0
Warnings
Earnings expected to drop: P/E 3.2 → Forward 11.2
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Below Avwap Earnings
Tailwinds
Confidence
Zealand Pharma A/S is a Denmark-based biotechnology firm specializing in the discovery and commercialization of peptide-based therapeutics. The company focuses primarily on metabolic and gastrointestinal disorders, maintaining a pipeline that targets conditions with high unmet medical needs, such as congenital hyperinsulinism and short bowel syndrome.
The companys commercial and clinical portfolio includes Zegalogue for severe hypoglycemia and glepaglutide, a GLP-2 analog currently in Phase III trials. Biotechnology firms operating in the peptide space often utilize platform technologies to improve the half-life and stability of naturally occurring proteins, allowing for less frequent dosing compared to traditional biologics.
Zealand Pharma operates a research-intensive business model common in the mid-cap healthcare sector, where value is driven by clinical trial progression and regulatory approvals. The company maintains a dual presence in European and U.S. markets to facilitate global distribution of its specialized delivery systems, including autoinjectors and artificial pancreas components.
- Obesity pipeline clinical data drives valuation and strategic partnership interest
- Glepaglutide Phase III results and regulatory filing for short bowel syndrome
- Dasiglucagon FDA approval timeline for congenital hyperinsulinism impacts commercial scaling
- R&D expenditure and capital raises dictate cash runway and dilution risk
| Net Income: 6.40b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.41 > 0.02 and ΔFCF/TA 54.77 > 1.0 |
| NWC/Revenue: 158.1% < 20% (prev 15.4k%; Δ -15.3k% < -1%) |
| CFO/TA 0.42 > 3% & CFO 6.36b > Net Income 6.40b |
| Net Debt (-13.9b) to EBITDA (6.74b): -2.07 < 3 |
| Current Ratio: 37.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (70.6m) vs 12m ago 0.02% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 75.67% > 50% (prev 0.61%; Δ 75.06% > 0%) |
| Interest Coverage Ratio: 180.1 > 6 (EBIT TTM 6.71b / Interest Expense TTM 37.2m) |
| A: 0.96 (Total Current Assets 15.0b - Total Current Liabilities 404.0m) / Total Assets 15.3b |
| B: -0.02 (Retained Earnings -356.0m / Total Assets 15.3b) |
| C: 0.55 (EBIT TTM 6.71b / Avg Total Assets 12.2b) |
| D: 17.39 (Book Value of Equity 14.5b / Total Liabilities 832.0m) |
| Altman-Z'' = 28.14 = AAA |
| DSRI: 0.10 (Receivables 239.0m/149.9m, Revenue 9.24b/55.7m) |
| GMI: 0.94 (GM 93.39% / 99.72%) |
| AQI: 2.05 (AQ_t 0.01 / AQ_t-1 0.00) |
| SGI: 165.9 (Revenue 9.24b / 55.7m) |
| TATA: 0.00 (NI 6.40b - CFO 6.36b) / TA 15.3b) |
| Beneish M = 115.0 (Cap -4..+1) = D |
As of June 20, 2026, the stock is trading at DKK 283.40 with a total of 393,965 shares traded.
Over the past week, the price has changed by -3.70%,
over one month by -9.34%,
over three months by +1.03% and
over the past year by -25.52%.
Zealand Pharma has no consensus analysts rating.
P/E Trailing = 3.1886
P/E Forward = 11.1607
P/S = 2.1496
P/B = 1.474
P/EG = 0.31
Revenue TTM = 9.24b DKK
EBIT TTM = 6.71b DKK
EBITDA TTM = 6.74b DKK
Long Term Debt = 307.0m DKK (from longTermDebt, last quarter)
Short Term Debt = 29.0m DKK (from shortTermDebt, last quarter)
Debt = 521.0m DKK (from shortLongTermDebtTotal, last quarter) + Leases 107.0m
Net Debt = -13.9b DKK (calculated: Debt 521.0m - CCE 14.5b)
Enterprise Value = 5.92b DKK (19.9b + Debt 521.0m - CCE 14.5b)
Interest Coverage Ratio = 180.1 (Ebit TTM 6.71b / Interest Expense TTM 37.2m)
EV/FCF = 0.94x (Enterprise Value 5.92b / FCF TTM 6.32b)
FCF Yield = 106.9% (FCF TTM 6.32b / Enterprise Value 5.92b)
FCF Margin = 68.43% (FCF TTM 6.32b / Revenue TTM 9.24b)
Net Margin = 69.22% (Net Income TTM 6.40b / Revenue TTM 9.24b)
Gross Margin = unknown ((Revenue TTM 9.24b - Cost of Revenue TTM 25.6m) / Revenue TTM)
Tobins Q-Ratio = 0.39 (Enterprise Value 5.92b / Total Assets 15.3b)
Interest Expense / Debt = 7.15% (Interest Expense 37.2m / Debt 521.0m)
Taxrate = 7.88% (547.4m / 6.94b)
NOPAT = 6.18b (EBIT 6.71b * (1 - 7.88%))
Current Ratio = 37.17 (Total Current Assets 15.0b / Total Current Liabilities 404.0m)
Debt / Equity = 0.04 (Debt 521.0m / totalStockholderEquity, last quarter 14.5b)
Debt / EBITDA = -2.07 (Net Debt -13.9b / EBITDA 6.74b)
Debt / FCF = -2.21 (Net Debt -13.9b / FCF TTM 6.32b)
Total Stockholder Equity = 15.0b (last 4 quarters mean from totalStockholderEquity)
RoA = 52.38% (Net Income 6.40b / Total Assets 15.3b)
RoE = 42.59% (Net Income TTM 6.40b / Total Stockholder Equity 15.0b)
RoCE = 43.78% (EBIT 6.71b / Capital Employed (Equity 15.0b + L.T.Debt 307.0m))
RoIC = 42.73% (NOPAT 6.18b / Invested Capital 14.5b)
WACC = 7.62% (E(19.9b)/V(20.4b) * Re(7.65%) + D(521.0m)/V(20.4b) * Rd(7.15%) * (1-Tc(0.08)))
Discount Rate = 7.65% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 42.22 | Cagr: 8.82%
[DCF] Terminal Value 75.44% ; FCFF base≈6.32b ; Y1≈6.35b ; Y5≈6.73b
[DCF] Fair Price = 1.70k (EV 105b - Net Debt -13.9b = Equity 119b / Shares 69.7m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.19 | # QB: 3
Revenue Correlation: 67.71 | Revenue CAGR: 391.5% | SUE: 0.06 | # QB: 0
EPS current Quarter (2026-06-30): EPS=14.18 | Chg30d=+696.24% | Revisions=N/A | Analysts=4
EPS next Quarter (2026-09-30): EPS=1.10 | Chg30d=-15.40% | Revisions=-20% | Analysts=4
EPS current Year (2026-12-31): EPS=21.91 | Chg30d=-3.97% | Revisions=+43% | GrowthEPS=-75.7% | GrowthRev=-50.0%
EPS next Year (2027-12-31): EPS=9.33 | Chg30d=+17.45% | Revisions=+54% | GrowthEPS=-57.4% | GrowthRev=-4.9%
[Analyst] Revisions Ratio: +54%